--- title: "KPV | PepTracker Pro" url: https://peptrackerpro.com/peptides/kpv description: "A tripeptide derived from alpha-MSH, studied for anti-inflammatory and gut-protective properties." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # KPV Medium Evidence A tripeptide derived from alpha-MSH, studied for anti-inflammatory and gut-protective properties. Aliases KPV tripeptide +2 more Evidence Medium Evidence Last Updated 2026-07-21 Reading Time 2 min ## What It Is KPV is a tripeptide (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (α-MSH). Research has explored its anti-inflammatory properties, particularly in the context of inflammatory bowel disease (IBD) models. Studies suggest it may exert anti-inflammatory effects through NF-κB pathway modulation without the melanotropic effects of the full α-MSH peptide. In 2026, expanded Phase II and nascent Phase III KPV clinical trial initiatives are exploring a broader spectrum of inflammatory and autoimmune conditions beyond initial IBD focus areas. Advanced delivery systems have shown promise: a KPV-based conjugate (proKPV) achieved 3.8-fold greater colonic accumulation than free KPV in colitis models, with enhanced efficacy even at a 20-fold lower dose — demonstrating superior therapeutic outcomes to 5-ASA (first-line colitis drug) in attenuating body weight loss, reducing disease activity scores, and suppressing pro-inflammatory cytokine production. KPV is one of four peptides scheduled for PCAC review on July 23, 2026, alongside BPC-157, TB-500, and MOTS-C, for potential addition to the 503A Bulks List. KPV's proposed therapeutic indications for the PCAC review include wound healing and inflammatory conditions. Public comments via docket FDA-2025-N-6895 are accepted until July 22, 2026. In a Phase IIb clinical trial, oral KPV (5 mg three times daily) achieved 67% endoscopic remission in ulcerative colitis patients at 12 weeks versus 23% placebo, with a 58% reduction in faecal calprotectin -- a key biomarker of intestinal inflammation. Based on these results, the FDA granted KPV fast-track designation in October 2025, accelerating its regulatory pathway toward potential Phase III evaluation. Also known as: KPV tripeptide, Lysine-Proline-Valine, alpha-MSH fragment ## Regulatory Status Category 1 — Bulk Compounding (PCAC review July 23, 2026) Moved from Category 2 back to Category 1 per HHS announcement February 27, 2026. FDA PCAC will review KPV (free base and acetate) on July 23, 2026 for potential 503A Bulks List inclusion for wound healing and inflammatory conditions. Public comment docket FDA-2025-N-6895 open until July 22, 2026. Effective: February 2026 View FDA Source (https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) ## Evidence Snapshot Medium Evidence Low Medium High | Study Type | Model | Outcome | Link | | --- | --- | --- | --- | | Animal (mouse) | DSS-induced colitis model — oral KPV | Reduced disease severity, improved weight recovery, and lowered inflammatory cytokine levels in colon tissue | Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC2431115/ | | Animal (mouse, 2026) | ProKPV conjugate in colitis — self-immolative delivery system | 3.8-fold greater colonic accumulation than free KPV; superior to 5-ASA at 20-fold lower dose; significant attenuation of body weight loss and disease activity | Source: https://www.science.org/doi/10.1126/sciadv.aea2989 | | In vitro | Human colonocytes — NF-κB pathway modulation | Direct inhibition of NF-κB activation and downstream inflammatory cascades without melanotropic effects | Source: https://pubmed.ncbi.nlm.nih.gov/18061177/ | | Human (Phase IIb) | Oral KPV 5mg TID in ulcerative colitis patients, 12 weeks | 67% endoscopic remission vs 23% placebo; 58% reduction in faecal calprotectin vs 12% placebo; FDA fast-track designation granted October 2025 | Source: https://www.realpeptides.co/kpv-clinical-trials-2026/ | ## Commonly Discussed Benefits Inflammation: https://peptrackerpro.com/benefits/inflammation Gut Health: https://peptrackerpro.com/benefits/gut-health Skin: https://peptrackerpro.com/benefits/skin Immune Support: https://peptrackerpro.com/benefits/immune-support Researching KPV? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=kpv) ## Safety & Cautions - Phase IIb data is promising but Phase III trials are still needed - No long-term human safety data beyond 12 weeks - Not FDA-approved for any condition - FDA fast-track designation does not guarantee approval - PCAC review scheduled July 23, 2026 for compounding eligibility ## Comparisons See how KPV compares to related peptides: KPV vs BPC-157: https://peptrackerpro.com/compare/kpv-vs-bpc-157 KPV vs Difelikefalin: https://peptrackerpro.com/compare/kpv-vs-difelikefalin KPV vs Efzofitimod: https://peptrackerpro.com/compare/kpv-vs-efzofitimod KPV vs MOTS-c: https://peptrackerpro.com/compare/kpv-vs-mots-c KPV vs TB-500: https://peptrackerpro.com/compare/kpv-vs-tb-500 KPV vs Thymosin Alpha-1: https://peptrackerpro.com/compare/kpv-vs-thymosin-alpha-1 KPV vs Zosurabalpin: https://peptrackerpro.com/compare/kpv-vs-zosurabalpin ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] Brzoska T. et al. — Alpha-MSH and its derivatives: anti-inflammatory effects. Ann N Y Acad Sci. 2008 PubMed (https://pubmed.ncbi.nlm.nih.gov/) 2. [2] PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation — Gastroenterology 2008 PubMed (https://pubmed.ncbi.nlm.nih.gov/18061177/) 3. [3] Inflammation-triggered self-immolative conjugates enable oral peptide delivery — Science Advances 2026 PubMed (https://www.science.org/doi/10.1126/sciadv.aea2989) 4. [4] Anti-Inflammatory Peptides as Promising Therapeutics Against IBD: A Systematic Review — JGH Open 2025 PubMed (https://onlinelibrary.wiley.com/doi/full/10.1002/jgh3.70212) 5. [5] FDA — July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee PubMed (https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) 6. [6] KPV Phase IIb Clinical Trial Results -- Endoscopic Remission in Ulcerative Colitis. 2025 PubMed (https://www.realpeptides.co/kpv-clinical-trials-2026/) ### Keep researching in the app - Log KPV to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=kpv Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### BPC-157 Medium Evidence A pentadecapeptide derived from human gastric juice, studied for tissue repair and gut-protective properties. Recovery (https://peptrackerpro.com/benefits/recovery)Gut Health (https://peptrackerpro.com/benefits/gut-health)Wound Healing (https://peptrackerpro.com/benefits/wound-healing)Joint Health (https://peptrackerpro.com/benefits/joint-health)+2 more View Details: https://peptrackerpro.com/peptides/bpc-157 \+ Compare: https://peptrackerpro.com/compare?select=bpc-157 Track in App: https://app.peptrackerpro.com/?add=bpc-157 ### Difelikefalin High Evidence Difelikefalin (Korsuva in the U.S., Kapruvia in Europe) is a synthetic tetrapeptide built entirely from D-amino acids - D-Phe-D-Phe-D-Leu-D-Lys capped with a 4-aminopiperidine-4-carboxylic acid - that acts as a selective agonist at the kappa opioid receptor. Its defining property is what it cannot do: the molecule is hydrophilic and bulky enough that it does not meaningfully cross the blood-brain barrier, so it reaches kappa receptors on peripheral sensory nerve endings, keratinocytes and immune cells while leaving the central kappa receptors that produce dysphoria and hallucinations largely untouched. It has no activity at the mu opioid receptor, so it carries neither euphoria nor respiratory depression. In the Phase 3 KALM-1 and KALM-2 trials in hemodialysis patients with moderate-to-severe chronic-kidney-disease-associated pruritus, roughly 40-51% of difelikefalin-treated patients achieved a clinically meaningful (>=3-point) reduction on the 10-point Worst Itching Intensity NRS at 12 weeks versus roughly 20-28% on placebo. The FDA approved intravenous difelikefalin in August 2021; the EU approved it as Kapruvia in April 2022. Pain Relief (https://peptrackerpro.com/benefits/pain-relief)Inflammation (https://peptrackerpro.com/benefits/inflammation)Skin (https://peptrackerpro.com/benefits/skin)Disease Modification (https://peptrackerpro.com/benefits/disease-modification)+1 more View Details: https://peptrackerpro.com/peptides/difelikefalin \+ Compare: https://peptrackerpro.com/compare?select=difelikefalin Track in App: https://app.peptrackerpro.com/?add=difelikefalin ### Efzofitimod Medium Evidence A first-in-class, intravenous immunomodulatory fusion peptide derived from histidyl-tRNA synthetase that selectively binds neuropilin-2 (NRP2) to dampen inflammation in the lung; in Phase 3 development for pulmonary sarcoidosis, an interstitial lung disease. Inflammation: https://peptrackerpro.com/benefits/inflammation Immune Support: https://peptrackerpro.com/benefits/immune-support View Details: https://peptrackerpro.com/peptides/efzofitimod \+ Compare: https://peptrackerpro.com/compare?select=efzofitimod Track in App: https://app.peptrackerpro.com/?add=efzofitimod ### MOTS-c Low Evidence A mitochondrial-derived peptide studied for metabolic regulation, exercise mimetic effects, and longevity. Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Longevity (https://peptrackerpro.com/benefits/longevity)Muscle Growth (https://peptrackerpro.com/benefits/muscle-growth)+2 more View Details: https://peptrackerpro.com/peptides/mots-c \+ Compare: https://peptrackerpro.com/compare?select=mots-c Track in App: https://app.peptrackerpro.com/?add=mots-c ### TB-500 Medium Evidence A naturally occurring peptide involved in cell migration and tissue repair, studied for wound healing and recovery. Recovery (https://peptrackerpro.com/benefits/recovery)Wound Healing (https://peptrackerpro.com/benefits/wound-healing)Inflammation (https://peptrackerpro.com/benefits/inflammation)Muscle Growth (https://peptrackerpro.com/benefits/muscle-growth)+1 more View Details: https://peptrackerpro.com/peptides/tb-500 \+ Compare: https://peptrackerpro.com/compare?select=tb-500 Track in App: https://app.peptrackerpro.com/?add=tb-500 ### Thymosin Alpha-1 High Evidence A thymic peptide approved in some countries for immune modulation, studied for viral infections and cancer adjunct therapy. Immune Support: https://peptrackerpro.com/benefits/immune-support Longevity: https://peptrackerpro.com/benefits/longevity Inflammation: https://peptrackerpro.com/benefits/inflammation View Details: https://peptrackerpro.com/peptides/thymosin-alpha-1 \+ Compare: https://peptrackerpro.com/compare?select=thymosin-alpha-1 Track in App: https://app.peptrackerpro.com/?add=thymosin-alpha-1 ### Zosurabalpin Medium Evidence A first-in-class tethered macrocyclic peptide antibiotic that kills carbapenem-resistant Acinetobacter baumannii (CRAB) by blocking the bacterium's lipopolysaccharide (LPS) transporter, now advancing into a global Phase 3 trial. Antimicrobial: https://peptrackerpro.com/benefits/antimicrobial View Details: https://peptrackerpro.com/peptides/zosurabalpin \+ Compare: https://peptrackerpro.com/compare?select=zosurabalpin Track in App: https://app.peptrackerpro.com/?add=zosurabalpin ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "KPV", "description": "A tripeptide derived from alpha-MSH, studied for anti-inflammatory and gut-protective properties.", "url": "https://peptrackerpro.com/peptides/kpv", "lastReviewed": "2026-07-21", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "KPV", "item": "https://peptrackerpro.com/peptides/kpv" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People researching anti-inflammatory peptides?", "acceptedAnswer": { "@type": "Answer", "text": "KPV is a research peptide studied in preclinical models. A tripeptide derived from alpha-MSH, studied for anti-inflammatory and gut-protective properties." } }, { "@type": "Question", "name": "Those exploring gut health and IBD research?", "acceptedAnswer": { "@type": "Answer", "text": "KPV is a research peptide studied in preclinical models. A tripeptide derived from alpha-MSH, studied for anti-inflammatory and gut-protective properties." } }, { "@type": "Question", "name": "Individuals interested in alpha-MSH derivatives?", "acceptedAnswer": { "@type": "Answer", "text": "KPV is a research peptide studied in preclinical models. A tripeptide derived from alpha-MSH, studied for anti-inflammatory and gut-protective properties." } } ] } ] ```